# The life-cycle of the HIV-1 Gag-RNA complex

Élodie Mailler, Serena Bernacchi, Roland Marquet, Jean-Christophe Paillart, Valerie Vivet Boudou, Redmond P Smyth

► To cite this version:

Élodie Mailler, Serena Bernacchi, Roland Marquet, Jean-Christophe Paillart, Valerie Vivet Boudou, et al.. The life-cycle of the HIV-1 Gag-RNA complex. Viruses, 2016, 8 (9), 10.3390/v8090248. [hal-05255386]

HAL Id: hal-05255386

https://univoak.hal.science/hal-05255386v1

Submitted on 13 Nov 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

Review

# The Life-Cycle of the HIV-1 Gag–RNA Complex

Elodie Mailler, Serena Bernacchi, Roland Marquet, Jean-Christophe Paillart, Valérie Vivet-Boudou * and Redmond P. Smyth *

Architecture et Réactivité de l'ARN, Université de Strasbourg, IBMC, CNRS, 15 rue René Descartes, 67084 Strasbourg, France; e.mailler@ibmc-cnrs.unistra.fr (E.M.); s.bernacchi@ibmc-cnrs.unistra.fr (S.B.); r.marquet@ibmc-cnrs.unistra.fr (R.M.); jc.paillart@ibmc-cnrs.unistra.fr (J.-C.P.)

* Correspondence: v.vivet@ibmc-cnrs.unistra.fr (V.V.-B.); r.smyth@ibmc-cnrs.unistra.fr (R.P.S.); Tel.: +33-(0)3-88-41-70-35 (V.V.-B.); +33-(0)3-88-41-70-40 (R.P.S.)

Academic Editor: Eric O. Freed

Received: 15 July 2016; Accepted: 2 September 2016; Published: 10 September 2016

**Abstract:** Human immunodeficiency virus type 1 (HIV-1) replication is a highly regulated process requiring the recruitment of viral and cellular components to the plasma membrane for assembly into infectious particles. This review highlights the recent process of understanding the selection of the genomic RNA (gRNA) by the viral Pr55Gag precursor polyprotein, and the processes leading to its incorporation into viral particles.

**Keywords:** HIV-1; packaging; Gag; genomic RNA; assembly

## 1. Introduction

Human immunodeficiency virus type 1 (HIV-1) replication is a highly regulated process requiring the recruitment of viral and cellular components to the plasma membrane for assembly into infectious particles. The Pr55Gag precursor polyprotein (Gag) is the minimal component required for HIV-1 assembly. It specifically recruits the viral genomic (gRNA) via its nucleocapsid (NC) domain, and drives viral assembly through the multimerization of its capsid (CA) domain at specific plasma membrane micro-domains targeted by the matrix (MA) domain [1–5]. The RNA genome acts as a scaffold for the multimerization of Gag and Gag–Pol precursors and is a key player in retrovirus assembly [6,7].

In order to generate an infectious particle, HIV-1 must selectively package two copies of its unspliced positive sense and single-stranded gRNA [8,9]. Genome encapsidation is highly specific, allowing the gRNA to be efficiently selected from a much larger pool of cellular and subgenomic viral RNA species (reviewed in [10,11]). This specificity is achieved through the recognition of *cis*-acting packaging signals by the Gag precursor protein which are also thought to be regulated by RNA conformational switches [12–16]. The major packaging signal comprises the 5' untranslated region (UTR), the beginning of the Gag coding sequence [17–23], and may include other regions within the gRNA [24–26]. The gRNA is initially selected in the cytoplasm by a limited number of Gag molecules. The Gag–RNA complex then nucleates viral assembly at the plasma membrane. However, the spatio-temporal parameters of gRNA recognition and viral assembly remain incomplete (Figure 1).

This review will summarize our current understanding of the HIV-1 Gag–RNA complex formation leading to its packaging into viral particles.
<figure><img src="image_3.png" /><figcaption>**Figure 1.** The late phase of retroviral cycle highlighting the dimerization event and the Gag–RNA complex formation. Full-length genomic RNA (gRNA) as well as singly and multi-spliced viral RNAs are produced by the host cell machinery and exported into the cytoplasm. Two copies of genomic RNA (gRNA) are encapsidated inside the newly synthesized viral particle as a dimer. The interaction of Gag with the gRNA in the cytoplasm ensures its specific encapsidation. Targeting of the Gag–RNA complex to the plasma membrane (PM) is promoted by host transfer RNA (tRNA) binding to the Gag matrix (MA) domain. Since the spatio-temporal parameters of these related events remain unclear, this figure depicts the different possibilities. CA: capsid; NC: nucleocapsid; RT: reverse transcriptase; PR: protease; IN: integrase; CRM1: Chromosomal Maintenance 1; LTR: long terminal repeat.</figcaption></figure>

## 2. Nuclear Export of Genomic RNA and Its Role in Particle Assembly

The HIV-1 replication cycle begins with the transcription of the proviral DNA by the host RNA polymerase II into full-length viral RNA that can subsequently be singly or multi-spliced [27]. This pool of viral RNA must traffic out of the nucleus into the cytoplasm to serve as messenger RNA (mRNA) for translation as well as gRNA for packaging. The host machinery normally prevents the export of single and unspliced viral RNA species, so retroviruses must circumvent this blockade. HIV-1 encodes the Rev protein which interacts with an RNA element called the Rev response element (RRE) and with the Chromosomal Maintenance 1 (CRM1)/RanGTP nuclear export complex [14,28–33].

Interestingly, several studies demonstrate a role for the RNA export pathway in HIV-1 assembly. Indeed, replacement of the HIV-1 RRE with the hepatitis B virus post-transcriptional regulatory element caused virus particles to accumulate intracellularly with slower kinetics despite similar levels of Gag expression compared to Rev-dependent Gag [34,35]. This mutant could be rescued in *cis* by replacing the MA domain with another membrane targeting domain, or in *trans* by expressing Gag from a Rev-dependent mRNA [35]. The defect was attributed to altered Gag localization due to inefficient plasma membrane targeting by MA when the viral mRNA is trafficked out of the nucleus by a Rev-independent pathway [35]. Interestingly, a similar relationship between HIV-1 RNA trafficking and productive Gag assembly was earlier reported in murine cells which normally do not support viral replication due, in part, to inefficient Gag plasma membrane targeting [27,36,37]. In this case, efficient budding could be induced upon modifying the gRNA export pathway [38,39], or through mutation of the MA domain to enhance membrane binding [40]. Taken together, these results suggest a strong influence of the nuclear export pathway on downstream cytoplasmic events leading to viral assembly. Of note, it was recently demonstrated that Rev dependent (containing RRE) and Rev independent (containing the Mason-Pfizer monkey virus (MPMV) constitutive transport element (CTE)) RNAs have
remarkably different trafficking behaviours when visualized in the cytoplasm [41]. RRE-containing RNAs exhibited "en masse" export into the cytoplasm, consistent with a diffusion based mechanism of transport [41,42], whereas MPMV CTE-containing RNAs clustered to the microtubule-organizing center (MTOC) [41]. This suggests that RNA export elements can impact later stages of the virus life-cycle through their distinct trafficking behaviours in the cytoplasm.

### 3. The Fate of Genomic RNA: Translation versus Packaging

The full length unspliced RNA serves as the mRNA template for Gag and Gag-Pol synthesis, as well as the genome for packaging. The fact that the cellular translation machinery and viral assembly could compete for cytoplasmic utilization of the gRNA implies a need to regulate these processes. Several groups have proposed models for the regulation of gRNA translation and packaging, but the interplay between these processes is poorly understood.

Experiments using inhibitors to block host cell transcription or translation show that simple retroviruses, such as murine leukaemia virus (MLV), segregate unspliced gRNA into two functionally distinct populations: one associated with ribosomes for translation and one for packaging into viral particles [43–45]. This seems not to be the case with HIV-1, as similar experiments show that unspliced RNA can serve interchangeably as mRNA for translation and gRNA for packaging [45]. Nevertheless, even with a single pool of gRNA, Gag may still co-translationally package its own mRNA, which would be useful as a mechanism to preferentially package unspliced gRNA over other RNA species. For HIV-2, prior translation is not absolutely necessary for packaging [45], but early reports showed that the Gag precursor can directly binds to its own mRNA enhancing its packaging [46,47]. Similarly, for HIV-1, although translation does not seem to be absolutely required [48], co-translational capture was suggested to enhance gRNA packaging [49,50]. However, co-translational packaging for both HIV-1 [51] and HIV-2 [52] is not universally accepted, as more recent studies showed efficient packaging of gRNA by Gag in *trans*. At least for HIV-1, the packaging signal is known to include the AUG start codon, and it is likely that previous results supporting a co-translational packaging mechanism were instead due to a direct disruption of the packaging signal.

### 4. Selection of the Full-Length Genome by Gag

#### 4.1. Gag

The specific binding of Gag to the gRNA directs its encapsidation into nascent virus particles. Gag is a polyprotein with four structural domains MA, CA, NC and p6 and two short spacer peptides, SP1 (p2) and SP2 (p1) (Figure 2A). The C-terminal domain of CA contains the protein dimerization interface, whereas the MA domain binds plasma membrane lipids. Membrane binding is directed by a bipartite signal: the myristoyl group at its N-terminus, which facilitates hydrophobic interactions with membranes, and the highly basic region (HBR) at the MA surface, which mediates electrostatic interactions with cellular lipids like phosphatidylinositol-4,5-bisphosphate (PIP₂) [42,43,53]. MA also interacts with nucleic acids [54,55], and this is now thought to regulate the interaction between Gag and cellular membranes [4,55–57]. The NC domain specifically interacts with the gRNA through its two CCHC-type zinc finger motifs [7,58,59]. However, in vitro assays demonstrate that Gag has a higher affinity for the gRNA than the NC domain alone, strongly suggesting that other domains contribute to the Gag-gRNA interaction [13,17,60–62]. NC binding to RNA promotes the multimerization of Gag during virus assembly [7], and assembly in vitro can be initiated by a variety of nucleic acids, including short DNA oligonucleotides [58]. Remarkably, NC of HIV-1 Gag can be functionally replaced with a leucine zipper protein-protein interaction domain elegantly demonstrating that RNA per se is not needed for viral assembly, but serves only to promote Gag-Gag multimerization [63–67].
<figure><img src="image_4.png" /><figcaption>**Figure 2.** Human immunodeficiency virus type 1 (HIV-1) genome and Gag organization. (A) The Pr55Gag protein. Major functions of the different domains are indicated; (B) The HIV-1 5' untranslated region (UTR) contains the major packaging region SL1-SL4. The major Gag binding domain comprises nucleotides 227-237 in the NL43 strain [68]; (C) A region overlapping the Gag-Pol frameshift signal and (D) the Rev response element (RRE), might also be implicated in packaging. ZF: zinc finger; MA: matrix; CA: capsid; NC: nucleocapsid; p1: spacer domain SP2; p2: spacer domain SP1; TAR: Tat responsive element; Poly-A: polyadenylation signal, U5: unique 5' region, PBS: primer binding site; SL: stem loop; DIS: dimerization initiation site; SD: splice donor; U3: unique 3' region; R: repeat region; PR: protease; RT: reverse transcriptase; int: integrase; vif: viral infectivity factor; vpu: viral protein U; vpr: viral protein R; gp: glycoprotein; nef: negative factor.</figcaption></figure>

## 4.2. Genomic RNA and the Packaging Signal

HIV-1 packages two copies of its RNA genome into each virion [69]. These genomes are non-covalently linked via a process known as genomic RNA dimerization [9]. The initial interaction between the two genomes occurs in a region called the dimer linkage structure present in the 5' UTR, also known as stem-loop 1 (SL1) [12,14,70-72]. The dimerization process requires a six-nucleotide palindromic sequence present in the SL1 apical loop known as the dimerization initiation site (DIS). For the HIV-1 B strain, this sequence is GC-rich and flanked by two 5' and one 3' unpaired nucleotides. It has been shown by mutagenesis and chemical probing that this palindromic sequence forms an intermolecular kissing loop-loop interaction [71-73], and it is now well accepted that SL1 plays an important role in multiple steps of the HIV-1 life-cycle, including reverse transcription [74,75], packaging [13,75,76] and recombination [77-79]. Interestingly, deletion of SL1 decreases the kinetics of dimer formation [80], but neither viral replication [74] nor RNA packaging [81-83] is completely abolished. Furthermore, gRNA extracted from SL1 deleted virions is dimeric with normal thermal stability [80,84], providing strong evidence that additional dimerization sites exist within the HIV-1 genome [81,85]. Even so, it is generally agreed that SL1 is the most important dimerization motif, and the location and function of these putative additional dimerization sites still need to be determined.

The HIV-1 5' UTR is highly structured and contains a large number of independent domains (Figure 2B) [86-90]. From 5' to 3' these are the Tat Responsive Element (TAR) stem-loop required for efficient transcription of the viral RNA; the poly-A hairpin which contains a repressed polyadenylation signal; the primer binding site (PBS) for initiation of reverse transcription. Downstream of the PBS, the packaging signal, or Psi region, folds into four stem-loop structures (SL1 to SL4) [22,23,87,91]. SL1 is the previously mentioned dimerization initiation site, SL2 contains the major splice donor site, and SL3 has been historically considered as the main packaging element [22,23,92]. SL4 contains the AUG start codon, but is fairly unstable and is commonly shown in an alternative base-pairing with the U5 region [12,15,16].

Early attempts to map the HIV-1 packaging signal using deletion mutants identified SL3 as the major packaging signal for HIV-1 [22,23,91]. However, the region SL1-SL4 is not sufficient to
direct heterologous RNA into HIV-1 virions [93], and efficient packaging usually requires additional
upstream and downstream sequences. Indeed, later efforts to determine the smallest segment of the
genome that is capable of packaging heterologous RNA led to conflicting results, with TAR [94], the
poly-A stem loop [95], PBS domain [96], SL1 [75,84,96,97], and the first nucleotides of Gag [20,51]
all shown to contribute to RNA packaging. Some of these conflicting data likely result from the fact
that early deletion studies did not take into account the secondary and tertiary structure of the RNA.
For instance, deletions of SL3 preserving the RNA fold only moderately affect packaging [87,91],
whereas deletions destroying it decrease packaging by a 100-fold or more [23]. Indeed, a study using
targeted deletions of SL1 to SL4 found that deletion of SL3 only reduces the packaging efficiency of the
gRNA by two-fold, whereas deletion of SL1 reduces it by five-fold [76]. This points to SL1 rather than
SL3 as the main packaging determinant of the gRNA.

It is assumed that HIV-1 packaging is mainly driven by a specific interaction between Gag and the gRNA. Until recent years many in vitro studies of the Gag–gRNA interaction were performed with GagΔp6 for ease of production and purification. However, the p6 domain is known to have an important role in viral assembly [98–100] and it is possible that GagΔp6 does not fully recapitulate RNA binding by the full length Pr55Gag precursor protein. Recently, Gag including the p6 domain was successfully purified [101], and extensively tested for binding in vitro to a large panel of gRNA mutants by biochemical and footprinting assays [13]. In agreement with packaging assays conducted in cells, deletion of SL1 had a more drastic effect on full length Gag binding in vitro compared to deletions in SL3. More importantly, footprinting and mutagenesis experiments clearly identified the basal part and internal loop of SL1 as the primary Gag binding site. This was confirmed using mutational interference mapping experiment (MIME), which is a ‘functional footprinting’ technique that can identify at single-nucleotide resolution RNA sequence and structure crucial for function [68]. MIME precisely defined a 110 nucleotide region (positions 227-337 in the NL43 strain) critical for full length Gag binding in vitro (Figure 2B), and quantitatively demonstrated that SL1 is more important for binding than SL3. These data are consistent with NC binding sites identified within the HIV-1 virus by chemical probing [102], and with the crosslinking immunoprecipitation with high-throughput sequencing (CLIP-seq) data of RNA bound to Gag in transfected cells [57].

A recent analysis combining photo crosslinking with selective 2'-hydroxyl acylation analyzed by primer extension (XL-SHAPE), using GagΔp6 identified multiple binding sites within the HIV-1 5' UTR, including the poly-A loop, a GU-rich region around nucleotide 120, the PBS domain, several sites within SL1, the internal loop of SL2, the apical loop of SL3, and regions flanking SL3 and the AUG start codon [103]. However, Gag–gRNA binding specificity has been shown to change during virion biogenesis [57], consequently, these additional sites may reflect different binding specificity for RNA of GagΔp6 compared to full length Gag, or alternatively these additional binding sites may be due to the non-competitive conditions used in this study. Other regions of the HIV-1 5' UTR are reported to be important for genome packaging, such as TAR [104,105], the poly-A stem loop [106] and the PBS domain [96], as well as distal RNA elements such as a region overlapping the Gag–Pol ribosomal frameshift signal [24] (Figure 2C) and the RRE (Figure 2D) [25,26]. Nevertheless, the role of these distal elements in genome packaging is still under debate, as RNA genomes containing mutations or deletions of the frameshift element [107], or containing the MPMV CTE instead of the RRE are nevertheless efficiently packaged into virions [108]. Whether these additional packaging signals are Gag–gRNA interaction sites, or reflect alternative mechanisms necessary for packaging, such as RNA localization or translational read-through, is not currently known.

4.3. *Discrimination between Spliced and Genomic RNA, and the Regulation of Gag Binding*

HIV-1 packaging of the gRNA dimer is strongly favored over abundant cellular RNAs and viral
spliced mRNA species. As previously described, the specific recognition motif for the Gag precursor
was identified as the internal loop and distal helix of SL1 [13,68]. These results were unexpected as SL1
is located 5' of the spliced donor site and is thus present both on the genomic and on the spliced viral
RNAs, suggesting a mechanism preventing Gag binding to SL1 in spliced viral RNA. Consistent with this idea, SL1 promotes exclusively the packaging of the unspliced gRNA, whereas spliced viral RNAs deleted for SL1 are incorporated with equal efficiency as spliced RNAs containing SL1 [76]. It was proposed that binding of the Gag precursor is controlled through a mechanism of double regulation: the region 5' of SL1, present on all viral RNAs, prevents binding of Gag to SL1, whilst a downstream region in the Gag gene, only present in the gRNA, abolishes this negative effect [13] (Figure 3A). This mechanism probably requires tertiary interactions that cooperate to build a high affinity Gag binding site, but these remain to be identified.

<figure><img src="image_5.png" /><figcaption>**Figure 3.** RNA structural models proposed to regulate the packaging and translation of the gRNA. (A) Gag binding is subjected to a mechanism of double regulation. The region upstream of SL1 (present in all viral RNAs) negatively regulates Gag binding. A region upstream of SL1 prevents binding of Gag to SL1 and this negative effect is counteracted by a motif downstream of SL4, present only in gRNA species; (B) The Long Distance Interaction (LDI) proposed to promote translation and the Branched Multiple Hairpin (BMH) proposed to promote packaging; (C) The U5 region is involved in alternative interactions with the dimerization initiation site (DIS) (promoting translation) and the region surrounding the AUG start codon (promoting packaging). A three-way junction, which further extends the U5-AUG interaction and eliminates SL2, is proposed to favour packaging. TAR: Tat responsive element; Poly-A: polyadenylation signal, U5: unique 5' region, PBS: primer binding site; SL: stem loop; DIS: dimerization initiation site; SD: splice donor; Psi: packaging signal; AUG; start codon.</figcaption></figure>

Given that the dimerization signal overlaps with the packaging signal, it is possible that Gag recognizes the gRNA dimer rather than two monomers. Evidence for this is provided by the observation that the duplication of the HIV-1 packaging site in one full length RNA leads to the packaging of the monomer with an intramolecular interaction [109]. Indeed, the dimerization and encapsidation of HIV-1 gRNA seem to be strongly interrelated processes [76,84,97,110–114], and this feature is observed in all retroviruses studied to date [9,18,115–117]. This has given rise to several
models where conformational changes in the gRNA regulate Gag binding through dimerization. The first model proposed a switch between the Branched Multiple Hairpins (BMH) and the Long Distance Interaction (LDI) structure [12,118] (Figure 3B). In the LDI, SL1 and poly-A base pair to form a long helix which sequesters, and renders inaccessible for dimerization, the DIS sequence. Conversely, the Gag start codon (AUG) is located in a bulge and proposed to be available for the RNA translation. In the BMH, SL1 to SL3 form stem-loop structures, and the AUG is found base-paired with Unique-5' region (U5), forming the so-called U5–AUG interaction. This conformation exposes SL1 to promote dimerization and packaging rather than translation [119]. Despite the attractiveness of this model, the LDI conformation has not been detected in cells [88,102], thus rendering any role of this conformation in the packaging of the gRNA very unlikely. On the contrary, the existence of the U5–AUG interaction is well supported by phylogenetic, biochemical and chemical probing data [12,102,120], and is reported to be conserved in HIV-2 [121]. Nuclear magnetic resonance (NMR) structural data showed that the U5–AUG interaction exists in equilibrium with an alternative interaction between the U5 region and the GC-rich loop of SL1 [16] (Figure 3C). In this model, the U5–AUG interaction promotes RNA dimerization and packaging through release of the DIS [122]. A more recent NMR study performed on a 155-nucleotide region of the HIV-1 RNA, comprising nucleotides 1-344, deleted for TAR, Poly-A and PBS, revealed the existence of a tandem three-way junction structure [15] (Figure 3C). This structure extends the U5–AUG interaction to include residues of the major splice donor site in SL2, whilst exposing unpaired and mismatched G residues thought to favour NCp7 binding [15]. Stabilising the U5–AUG interaction stimulates recovery of RNA dimers isolated from cells [123], and mutations to the region surrounding the Gag AUG start codon inhibit packaging [15,16,51]. Furthermore, biophysical measurements show that disrupting the U5–AUG interaction decreases binding of the mature NCp7 protein [15]. However, not all mutations to SL4 predicted to disrupt the U5–AUG interaction affect binding of the full length Gag precursor protein in vitro [13,68], and mutations stabilising SL2 but disrupting the three-way junction surprisingly enhanced Gag binding in one in vitro study [68]. One possible interpretation is that the U5–AUG interaction is not involved in the initial recognition of the gRNA by the Gag precursor protein, but acts at a later stage of packaging after NCp7 is processed.

### 4.4. *The Role of Cellular RNAs*

Up to 50% of the HIV-1 packaged RNAs are from the cellular host [93,124], including 7SL RNAs, tRNAs and ribosomal RNAs (rRNAs) [124–127]. Whilst the packaging of spliced viral RNAs has been shown to be specific, and competes with the gRNA for binding to Gag, cellular RNAs are packaged via different and uncertain mechanism(s) [76], and their precise role in the virus life-cycle remain unclear (reviewed in [128,129]).

RNA is known to aid viral assembly by promoting Gag oligomerization [62,130,131], but also regulates binding of the Gag precursor to cellular membranes. The MA domain at the N terminus of HIV-1 Gag is positively charged, and can interact with RNAs and cellular lipids, such as PIP~2~ [54,55]. Intriguingly, the MA–RNA and PIP~2~ binding sites overlap, giving rise to the idea that cellular RNA directs MA to the appropriate cellular membrane [55–57]. Strikingly, CLIP-seq experiments performed in cells revealed that the basic region of MA binds to a subset of tRNAs [57]. Thus, HIV-1 Gag uses cellular tRNAs to regulate membrane binding, probably to prevent non-productive intracellular assembly.

## 5. Where Does the Gag–RNA Interaction Occur?

Imaging techniques have the potential to directly visualise Gag–RNA interactions at the scale of individual molecules in real time. Recent advances have begun to shed light on viral assembly from the initial selection of the gRNA by Gag to virus particle assembly at the plasma membrane [132].

In respiratory syncytial virus (RSV), a simple retrovirus, a small proportion of Gag traffics into the nucleus, and this was reported to be required for the efficient encapsidation of unspliced genomes [133,134]. Within the nucleus, RSV Gag binding to the gRNA stimulates its association with
the CRM1/RanGTP export complex, leading to its export and packaging [135,136]. Nuclear trafficking is dependent on the MA domain, and is undetectable in an RSV chimera containing HIV-1 MA [137]. Interestingly, this HIV-RSV chimera was still able to generate infectious virus, indicating that nuclear trafficking may not be absolutely required, or alternatively that low levels of residual shuttling may be sufficient for genome packaging [137]. In HIV-1, unspliced RNA is exported from the nucleus using the Rev protein, abrogating the need for Gag trafficking [136]. Nevertheless, the HIV-1 NC domain has been reported to contain a nuclear localization signal that can localize Gag to the nucleoli [138,139], but the functional significance of this is unclear and controversial [137,140].

For HIV-1, the initial Gag-gRNA interaction is thought to occur in the cytoplasm [131,141-144]. Genetic evidence, using a recombination-based assay, clearly shows that encapsidation occurs after RNA export from the nucleus [82,108]. However, attempts to image the first interaction site within cells have led to conflicting results, with one study identifying this site as the perinuclear/centrosomal region [145], whilst most other studies failed to observe a specific subcellular localization [131,141,143]. Within the cell, biochemical and imaging studies identify two different oligomerization states of Gag, depending on the timing of viral assembly and release: as a monomer or low-order oligomers in the cytosol [131], and high order multimers found preferentially at the plasma membrane [57,131,144]. Cytosolic oligomerisation depends on the NC domain, indicating a role for RNA in this process [131], but is independent of the ability of Gag to bind to membranes [57,144]. Interestingly, it has been observed that the Gag precursor protein is likely a trimer in solution [13], and in vitro assays showed that about six Gag molecules associate with one gRNA molecule with high affinity [146]. Taken together, these data support the notion that gRNA selection initiates in the cytoplasm and involves a very limited number of Gag molecules, which are then transported to the plasma membrane for assembly.

## 6. Transport of the Gag-RNA Complexes to Assembly Sites

A subcomplex comprising the gRNA and a few Gag proteins must traffic through the cytoplasm to sites of assembly. A dense network of actin filaments underneath the plasma membrane is visualized at HIV-1 budding sites, and viral particles have been shown to contain substantial amounts of actin [147], but its involvement in the assembly process has not been clearly demonstrated [148-150]. Live cell imaging by fluorescence microscopy and single-molecule tracking have revealed that in the absence of Gag, the HIV-1 gRNA moves randomly within the cell, indicating that it is not actively transported through the cytoplasm [42]. Furthermore, treatment of cells with cytochalasin-D and nocodazole demonstrate that an intact cytoskeletal structure is not required for HIV-1 RNA trafficking, consistent with diffusion as the major transport mechanism [42]. Many cellular proteins, such as ATP binding cassette subfamily E member 1 (ABCE1) [151,152], Staufen1 [153] and DEAD-box helicase 6 (DDX6) [154], traffic with the Gag-gRNA complexes to the plasma membrane. Staufen-1 binds the gRNA and is thought to be involved in packaging [153,155], but in general, the mechanism, purpose and path of these cellular-Gag-gRNA complexes remain poorly understood [156].

Reports initially supported a "late endosomal" model for HIV-1 assembly based on the fact that a significant proportion of Gag was found to localize in cellular compartments containing endosomal markers, like CD63 and lysosome-associated membrane protein-1 (Lamp-1) [157-159]. However, it was later realized that visualization of CD63-positive invaginations of the plasma membrane by electron microscopy could be mistaken for intracellular compartments containing viruses [149,160]. This hypothesis was confirmed by using two pharmacological inhibitors that abolish late endosome motility without affecting the amount of released particles [149]. Immunofluorescence studies also showed that Gag is first targeted to the plasma membrane and thereafter a population of virions can subsequently be internalized in late endosomes [149]. Taken together, these data are not consistent with HIV-1 endosomal trafficking pathway.

Total internal reflection fluorescence (TIRF) microscopy is an imaging technique that can visualize the Gag-gRNA interaction at the plasma membrane [110,161,162]. TIRF studies show that in the absence of Gag, gRNA only appears transiently at the membrane [161,162], whereas in the
presence of Gag, the gRNA is able to anchor at the membrane in a packaging signal dependent manner [110,143,149]. Anchoring is invariably followed by the rapid accumulation of Gag and the formation of a viral particle [110,161]. RNA dimerization is important for Gag binding and genome packaging, but it is unknown whether genome dimerization occurs before Gag binding and trafficking to the plasma membrane. One of the early TIRF studies proposed that preformed gRNA dimers are recruited to sites of assembly, since the RNA fluorescence signal never increased once at the plasma membrane together with Gag [161]. However, this picture has been revised based on a two colour TIRF imaging system that can directly visualize RNA dimerization at sites of viral assembly [110]. Surprisingly, dimerization was frequently seen to occur at the membrane, rather than being recruited preformed from the cytoplasm, and in a few cases RNA dimerization could still be observed at late stages of assembly [110]. Importantly, however, a recent two colour super-resolution microscopy study observed significant levels of RNA dimerization already in the cytoplasm, albeit with higher levels at the plasma membrane [141]. One possible way to reconcile these observations is to consider that Gag initiates RNA dimerization and/or stabilizes gRNA dimers in the cytoplasm, but that RNA dimerization remains dynamic at the membrane until virus assembly is completed [110,141].

## 7. Maturation

After assembly and the release from host cells, virions undergo a process of maturation leading to morphological rearrangements of the particle with the formation of the core and increased stability of the RNA dimer [3]. The proteolytic processing of the Pr55Gag and Pr160Gag-Pol precursors, performed by the viral protease, allows the production of the structural proteins and is required for the morphological rearrangement of the viral particle [163]. This process is believed to happen during or quickly following budding of the immature particle [164]. Proteolytic processing is highly regulated temporally as protease inhibitor wash-out experiments clearly demonstrate that the timing of proteolytic processing is critical for the acquisition of infectivity [165], and viral infectivity is blocked even at concentrations of inhibitor showing little to no effect on Gag processing [166,167]. Concomitant with proteolytic processing the gRNA is rearranged from a “loose” unstable dimer to a “tight” dimer that has slower electrophoretic mobility and altered thermal stability compared to dimers isolated from immature viruses [80,168].

The maturation process is crucial for the acquisition of viral infectivity and multiple lines of evidence indicate a link between proteolytic processing and the structural maturation of the gRNA. For Moloney murine leukemia virus (MuLV), immature genomes isolated from protease negative virions adopt an unstable conformation with fewer intergenome interactions when compared to mature virus [169]. RNA genomes isolated from protease defective HIV-1 are unstable, much like RNA dimers isolated from immature viruses [170,171]. The production of the different structural proteins therefore seems important for the structural maturation of the gRNA. The NCp7 protein is well-known for its nucleic-acid chaperone activity and is the leading candidate for causing RNA dimer stabilization [172–174]. Cryo-electron tomography and subtomogram averaging highlighted the importance of the primary cleavage between p2 and NC domains of Gag to initiate dimer RNA stabilization, while the ensuing cleavages are necessary to complete the process [175]. This change in NC RNA chaperone activity during proteolytic processing [60,176–178] is likely to regulate reverse transcription through multiple mechanisms including the promotion of stable tRNA annealing [179,180], facilitation of strand transfer [181–183], regulation of reverse transcription initiation [184–186], and the general remodelling of RNA structure, possibly to prevent reverse transcriptase stalling [187,188]. Recently, the impact of the RNA genome on proteolytic processing has also started to be evaluated. The analysis of the proteolytic processing pattern of HIV-1 [189] and HIV-2 [190] dimerization mutants indicates an accumulation of the p41 (MA-CA-p2) intermediate. Dimerization and the RNA genome thus could have an impact on particle assembly by modulating Gag processing [173].
## 8. Conclusions

The selection of the gRNA from the cytoplasm and its recruitment into budding virions by Gag is a remarkable process, and recent studies have only begun to reveal its complexity. Although tremendous progress has been made, clearly our understanding is far from being complete. Important questions remain regarding the selection of the full-length gRNA by Gag, and in particular the mechanistic details of how this process is regulated. From the viewpoint of the RNA genome, there are several proposed structural models of the 5' UTR that are yet to be integrated, which point towards a conformational flexibility that is most certainly involved in the regulation of the viral life cycle. Further advances in RNA structural analysis are likely needed to resolve (1) how Gag selects between genomic and spliced viral RNAs; (2) how RNA structural switches control translation versus packaging; and (3) the location of long hypothesized dimerization sites outside of SL1. From the viewpoint of the Gag protein, most binding studies have been performed using unmyristoylated GagΔp6, which may not completely reflect the properties of myristoylated full length Gag found in cells. Given the importance of both the myristoyl group and the p6 domain to virus assembly, it is tempting to speculate that these features could impact the Gag-gRNA interaction. Finally, a major limitation of existing imaging techniques is their inability to detect low numbers of Gag molecules, and this has so far prevented the unambiguous determination of where and when Gag first interacts with the gRNA. Improved imaging technologies are sure to address this problem in the near future.

**Acknowledgments:** This work was supported by grants from Sidaction and the French Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS). Redmond P. Smyth was supported by fellowships from the ANRS and from the Initiative d'excellence (IDEX), Par-delà les frontières, l'Université de Strasbourg. Elodie Mailler was supported by fellowship from the Fondation pour la Recherche Médicale en France (FDT20160435353).

**Author Contributions:** E.M., S.B., R.M., J.-C.P., V.V.-B. and R.P.S. wrote the review.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Ono, A. Relationships between plasma membrane microdomains and HIV-1 assembly. *Biol. Cell* **2010**, *102*, 335-350. [CrossRef] [PubMed]

2. Turner, B.G.; Summers, M.F. Structural biology of HIV. *J. Mol. Biol.* **1999**, *285*, 1-32. [CrossRef] [PubMed]

3. Sundquist, W.I.; Kräusslich, H.-G. HIV-1 assembly, budding, and maturation. *Cold Spring Harb. Perspect. Med.* **2012**, *2*, a006924. [CrossRef] [PubMed]

4. Carlson, L.-A.; Bai, Y.; Keane, S.C.; Doudna, J.A.; Hurley, J.H. Reconstitution of selective HIV-1 RNA packaging in vitro by membrane-bound Gag assemblies. *Elife* **2016**, *5*, 1-19. [CrossRef] [PubMed]

5. Freed, E.O. HIV-1 assembly, release and maturation. *Nat. Rev. Microbiol.* **2015**, *13*, 484-496. [CrossRef] [PubMed]

6. Burniston, M.T.; Cimarelli, A.; Colgan, J.; Curtis, S.P.; Luban, J. Human immunodeficiency virus type 1 Gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and the basic region of matrix protein. *J. Virol.* **1999**, *73*, 8527-8540. [PubMed]

7. Muriaux, D.; Mirro, J.; Harvin, D.; Rein, A. RNA is a structural element in retrovirus particles. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 5246-5251. [CrossRef] [PubMed]

8. Moore, M.D.; Hu, W.S. HIV-1 RNA dimerization: It takes two to tango. *AIDS Rev.* **2009**, *11*, 91-102. [PubMed]

9. Paillart, J.-C.; Shehu-Xhilaga, M.; Marquet, R.; Mak, J. Dimerization of retroviral RNA genomes: An inseparable pair. *Nat. Rev. Microbiol.* **2004**, *2*, 461-472. [CrossRef] [PubMed]

10. Kuzembayeva, M.; Dilley, K.; Sardo, L.; Hu, W.S. Life of psi: How full-length HIV-1 RNAs become packaged genomes in the viral particles. *Virology* **2014**, *454-455*, 362-370. [CrossRef] [PubMed]

11. Olson, E.D.; Cantara, W.A.; Musier-Forsyth, K. New structure sheds light on selective HIV-1 genomic RNA packaging. *Viruses* **2015**, *7*, 4826-4835. [CrossRef] [PubMed]

12. Abbink, T.E.M.; Berkhout, B. A novel long distance base-pairing interaction in human immunodeficiency virus type 1 RNA occludes the Gag start codon. *J. Biol. Chem.* **2003**, *278*, 11601-11611. [CrossRef] [PubMed]
13. Abd El-Wahab, E.W.; Smyth, R.P.; Mailler, E.; Bernacchi, S.; Vivet-Boudou, V.; Hijnen, M.; Jossinet, F.; Mak, J.; Paillart, J.-C.; Marquet, R. Specific recognition of the HIV-1 genomic RNA by the Gag precursor. *Nat. Commun.* **2014**, *5*, 4304. [CrossRef] [PubMed]

14. Van Bel, N.; Das, A.T.; Cornelissen, M.T.E.; Abbink, T.E.M.; Berkhout, B. A short sequence motif in the 5' leader of the HIV-1 genome modulates extended RNA dimer formation and virus replication. *J. Biol. Chem.* **2014**, *289*, 35061–35074. [CrossRef] [PubMed]

15. Keane, S.C.; Heng, X.; Lu, K.; Kharytonchyk, S.; Ramakrishnan, V.; Carter, G.; Barton, S.; Hosic, A.; Florwick, A.; Santos, J.; et al. RNA structure. Structure of the HIV-1 RNA packaging signal. *Science* **2015**, *348*, 917–921. [CrossRef] [PubMed]

16. Lu, K.; Heng, X.; Garyu, L.; Monti, S.; Garcia, E.L.; Kharytonchyk, S.; Dorjsuren, B.; Kulandaivel, G.; Jones, S.; Hiremath, A.; et al. NMR detection of structures in the HIV-1 5'-leader RNA that regulate genome packaging. *Science* **2011**, *334*, 242–245. [CrossRef] [PubMed]

17. Berkowitz, R.D.; Luban, J.; Goff, S.P. Specific binding of human immunodeficiency virus type 1 Gag polyprotein and nucleocapsid protein to viral RNAs detected by RNA mobility shift assays. *J. Virol.* **1993**, *67*, 7190–7200. [PubMed]

18. Lu, K.; Heng, X.; Summers, M.F. Structural determinants and mechanism of HIV-1 genome packaging. *J. Mol. Biol.* **2011**, *410*, 609–633. [CrossRef] [PubMed]

19. Luban, J.; Goff, S.P. Binding of human immunodeficiency virus type 1 (HIV-1) RNA to recombinant HIV-1 Gag polyprotein. *J. Virol.* **1991**, *65*, 3203–3212. [PubMed]

20. Luban, J.; Goff, S.P. Mutational analysis of cis-acting packaging signals in human immunodeficiency virus type 1 RNA. *J. Virol.* **1994**, *68*, 3784–3793. [PubMed]

21. McBride, M.S.; Panganiban, A.T. The human immunodeficiency virus type 1 encapsidation site is a multipartite RNA element composed of functional hairpin structures. *J. Virol.* **1996**, *70*, 2963–2973. [PubMed]

22. Lever, A.; Gottlinger, H.; Haseltine, W.; Sodroski, J. Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions. *J. Virol.* **1989**, *63*, 4085–4087. [PubMed]

23. Aldovini, A.; Young, R.A. Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus. *J. Virol.* **1990**, *64*, 1920–1926. [PubMed]

24. Chamanian, M.; Purzycka, K.J.; Wille, P.T.; Ha, J.S.; McDonald, D.; Gao, Y.; Le Grice, S.F.J.; Arts, E.J. A cis-acting element in retroviral genomic RNA links Gag-Pol ribosomal frameshifting to selective viral RNA encapsidation. *Cell Host Microbe* **2013**, *13*, 181–192. [CrossRef] [PubMed]

25. Grewe, B.; Ehrhardt, K.; Hoffmann, B.; Blissenbach, M.; Brandt, S.; Uberla, K. The HIV-1 Rev protein enhances encapsidation of unspliced and spliced, RRE-containing lentiviral vector RNA. *PLoS ONE* **2012**, *7*, e48688. [CrossRef] [PubMed]

26. Brandt, S.; Blissenbach, M.; Grewe, B.; Konietzny, R.; Grunwald, T.; Uberla, K. Rev proteins of human and simian immunodeficiency virus enhance RNA encapsidation. *PLoS Pathog.* **2007**, *3*, e54. [CrossRef] [PubMed]

27. Purcell, D.F.; Martin, M.A. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. *J. Virol.* **1993**, *67*, 6365–6378. [PubMed]

28. Malim, M.H.; Hauber, J.; Le, S.Y.; Maizel, J.V.; Cullen, B.R. The HIV-1 Rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. *Nature* **1989**, *338*, 254–257. [CrossRef] [PubMed]

29. Felber, B.K.; Hadzopoulou-Cladaras, M.; Cladaras, C.; Copeland, T.; Pavlakis, G.N. Rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. *Proc. Natl. Acad. Sci. USA* **1989**, *86*, 1495–1499. [CrossRef] [PubMed]

30. Daly, T.J.; Cook, K.S.; Gray, G.S.; Maione, T.E.; Rusche, J.R. Specific binding of HIV-1 recombinant Rev protein to the Rev-responsive element in vitro. *Nature* **1989**, *342*, 816–819. [CrossRef] [PubMed]

31. Wen, W.; Meinkoth, J.L.; Tsien, R.Y.; Taylor, S.S. Identification of a signal for rapid export of proteins from the nucleus. *Cell* **1995**, *82*, 463–473. [CrossRef]

32. Fornerod, M.; Ohno, M.; Yoshida, M.; Mattaj, I.W. CRM1 is an export receptor for leucine-rich nuclear export signals. *Cell* **1997**, *90*, 1051–1060. [CrossRef]

33. Pollard, V.W.; Malim, M.H. The HIV-1 Rev protein. *Annu. Rev. Microbiol.* **1998**, *52*, 491–532. [CrossRef] [PubMed]
34. Jin, J.; Sturgeon, T.; Chen, C.; Watkins, S.C.; Weisz, O.A.; Montelaro, R.C. Distinct intracellular trafficking of equine infectious anemia virus and human immunodeficiency virus type 1 Gag during viral assembly and budding revealed by bimolecular fluorescence complementation assays. *J. Virol.* **2007**, *81*, 11226–11235.
[CrossRef] [PubMed]

35. Jin, J.; Sturgeon, T.; Weisz, O.A.; Mothes, W.; Montelaro, R.C. HIV-1 matrix dependent membrane targeting is regulated by Gag mRNA trafficking. *PLoS ONE* **2009**, *4*, e6551. [CrossRef] [PubMed]

36. Mariani, R.; Rutter, G.; Harris, M.E.; Hope, T.J.; Kräusslich, H.G.; Landau, N.R. A block to human immunodeficiency virus type 1 assembly in murine cells. *J. Virol.* **2000**, *74*, 3859–3870. [CrossRef] [PubMed]

37. Chen, B.K.; Rousso, I.; Shim, S.; Kim, P.S. Efficient assembly of an HIV-1/MLV Gag-chimeric virus in murine cells. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 15239–15244. [CrossRef] [PubMed]

38. Sherer, N.M.; Swanson, C.M.; Papaioannou, S.; Malim, M.H. Matrix mediates the functional link between human immunodeficiency virus type 1 RNA nuclear export elements and the assembly competency of Gag in murine cells. *J. Virol.* **2009**, *83*, 8525–8535. [CrossRef] [PubMed]

39. Swanson, C.M.; Puffer, B.A.; Ahmad, K.M.; Doms, R.W.; Malim, M.H. Retroviral mRNA nuclear export elements regulate protein function and virion assembly. *EMBO J.* **2004**, *23*, 2632–2640. [CrossRef] [PubMed]

40. Hatziioannou, T.; Martin-Serrano, J.; Zang, T.; Bieniasz, P.D. Matrix-induced inhibition of membrane binding contributes to human immunodeficiency virus type 1 particle assembly defects in murine cells. *J. Virol.* **2005**, *79*, 15586–15589. [CrossRef] [PubMed]

41. Pocock, G.M.; Becker, J.T.; Swanson, C.M.; Ahlquist, P.; Sherer, N.M. HIV-1 and M-PMV RNA nuclear export elements program viral genomes for distinct cytoplasmic trafficking Behaviors. *PLoS Pathog.* **2016**, *12*, e1005565. [CrossRef] [PubMed]

42. Chen, J.; Grunwald, D.; Sardo, L.; Galli, A.; Plisov, S.; Nikolaitchik, O.A.; Chen, D.; Lockett, S.; Larson, D.R.; Pathak, V.K.; et al. Cytoplasmic HIV-1 RNA is mainly transported by diffusion in the presence or absence of Gag protein. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, E5205–E5213. [CrossRef] [PubMed]

43. Levin, J.G.; Rosenak, M.J. Synthesis of murine leukemia virus proteins associated with virions assembled in actinomycin D-treated cells: Evidence for persistence of viral messenger RNA. *Proc. Natl. Acad. Sci. USA* **1976**, *73*, 1154–1158. [CrossRef] [PubMed]

44. Messer, L.I.; Levin, J.G.; Chattopadhyay, S.K. Metabolism of viral RNA in murine leukemia virus-infected cells; evidence for differential stability of viral message and virion precursor RNA. *J. Virol.* **1981**, *40*, 683–690.
[PubMed]

45. Dorman, N.; Lever, A. Comparison of viral genomic RNA sorting mechanisms in human immunodeficiency virus type 1 (HIV-1), HIV-2, and Moloney murine leukemia virus. *J. Virol.* **2000**, *74*, 11413–11417. [CrossRef] [PubMed]

46. Griffin, S.D.; Allen, J.F.; Lever, A.M. The major human immunodeficiency virus type 2 (HIV-2) packaging signal is present on all HIV-2 RNA species: Cotranslational RNA encapsidation and limitation of Gag protein confer specificity. *J. Virol.* **2001**, *75*, 12058–12069. [CrossRef] [PubMed]

47. Kaye, J.F.; Lever, A.M. Human immunodeficiency virus types 1 and 2 differ in the predominant mechanism used for selection of genomic RNA for encapsidation. *J. Virol.* **1999**, *73*, 3023–3031. [PubMed]

48. Butsch, M.; Boris-Lawrie, K. Translation is not required To generate virion precursor RNA in human immunodeficiency virus type 1-infected T cells. *J. Virol.* **2000**, *74*, 11531–11537. [CrossRef] [PubMed]

49. Poon, D.T.K.; Chertova, E.N.; Ott, D.E. Human immunodeficiency virus type 1 preferentially encapsidates genomic RNAs that encode Pr55(Gag): Functional linkage between translation and RNA packaging. *Virology* **2002**, *293*, 368–378. [CrossRef] [PubMed]

50. Liang, C.; Hu, J.; Russell, R.S.; Wainberg, M.A. Translation of Pr55(Gag) augments packaging of human immunodeficiency virus type 1 RNA in a cis-acting manner. *AIDS Res. Hum. Retroviruses* **2002**, *18*, 1117–1126.
[CrossRef] [PubMed]

51. Nikolaitchik, O.A.; Rhodes, T.D.; Ott, D.; Hu, W.-S. Effects of mutations in the human immunodeficiency virus type 1 Gag gene on RNA packaging and recombination. *J. Virol.* **2006**, *80*, 4691–4697. [CrossRef] [PubMed]

52. Ni, N.; Nikolaitchik, O.A.; Dilley, K.A.; Chen, J.; Galli, A.; Fu, W.; Prasad, V.V.S.P.; Ptak, R.G.; Pathak, V.K.; Hu, W.-S. Mechanisms of human immunodeficiency virus type 2 RNA packaging: Efficient trans packaging and selection of RNA copackaging partners. *J. Virol.* **2011**, *85*, 7603–7612. [CrossRef] [PubMed]

53. Olety, B.; Ono, A. Roles played by acidic lipids in HIV-1 Gag membrane binding. *Virus Res.* **2014**, *193*, 108–115. [CrossRef] [PubMed]
54. Alfadhli, A.; Still, A.; Barklis, E. Analysis of human immunodeficiency virus type 1 matrix binding to membranes and nucleic acids. *J. Virol.* **2009**, *83*, 12196–12203. [CrossRef] [PubMed]

55. Chukkapalli, V.; Oh, S.J.; Ono, A. Opposing mechanisms involving RNA and lipids regulate HIV-1 Gag membrane binding through the highly basic region of the matrix domain. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 1600–1605. [CrossRef] [PubMed]

56. Alfadhli, A.; McNett, H.; Tsagli, S.; Bächinger, H.P.; Peyton, D.H.; Barklis, E. HIV-1 matrix protein binding to RNA. *J. Mol. Biol.* **2011**, *410*, 653–666. [CrossRef] [PubMed]

57. Kutluay, S.B.; Zang, T.; Blanco-melo, D.; Powell, C.; Jannain, D.; Errando, M. Global changes in the RNA binding specificity of HIV-1 Gag regulate virion genesis. *Cell* **2014**, *159*, 1096–1109. [CrossRef] [PubMed]

58. Campbell, S.; Rein, A. In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain. *J. Virol.* **1999**, *73*, 2270–2279. [PubMed]

59. Cimarelli, A.; Sandin, S.; Höglund, S.; Luban, J. Basic residues in human immunodeficiency virus type 1 nucleocapsid promote virion assembly via interaction with RNA. *J. Virol.* **2000**, *74*, 3046–3057. [CrossRef] [PubMed]

60. Cruceanu, M.; Urbaneja, M.A.; Hixson, C.V.; Johnson, D.G.; Datta, S.A.; Fivash, M.J.; Stephen, A.G.; Fisher, R.J.; Gorelick, R.J.; Casas-Finet, J.R.; et al. Nucleic acid binding and chaperone properties of HIV-1 Gag and nucleocapsid proteins. *Nucleic Acids Res.* **2006**, *34*, 593–605. [CrossRef] [PubMed]

61. Damgaard, C.K.; Dyhr-Mikkelsen, H.; Kjems, J. Mapping the RNA binding sites for human immunodeficiency virus type-1 Gag and NC proteins within the complete HIV-1 and -2 untranslated leader regions. *Nucleic Acids Res.* **1998**, *26*, 3667–3676. [CrossRef] [PubMed]

62. Rein, A.; Datta, S.A.K.; Jones, C.P.; Musier-Forsyth, K. Diverse interactions of retroviral Gag proteins with RNAs. *Trends Biochem. Sci.* **2011**, *36*, 373–380. [PubMed]

63. Crist, R.M.; Datta, S.A.K.; Stephen, A.G.; Soheilian, F.; Mirro, J.; Fisher, R.J.; Nagashima, K.; Rein, A. Assembly properties of human immunodeficiency virus type 1 Gag-leucine zipper chimeras: Implications for retrovirus assembly. *J. Virol.* **2009**, *83*, 2216–2225. [CrossRef] [PubMed]

64. Klein, K.C.; Reed, J.C.; Tanaka, M.; Nguyen, V.T.; Giri, S.; Lingappa, J.R. HIV Gag-leucine zipper chimeras form ABCE1-containing intermediates and RNase-resistant immature capsids similar to those formed by wild-type HIV-1 Gag. *J. Virol.* **2011**, *85*, 7419–7435. [CrossRef] [PubMed]

65. Mattei, S.; Flemming, A.; Anders-Össwein, M.; Kräusslich, H.-G.; Briggs, J.A.G.; Müller, B. RNA and nucleocapsid are dispensable for mature HIV-1 capsid assembly. *J. Virol.* **2015**, *89*, 9739–9747. [CrossRef] [PubMed]

66. Accola, M.A.; Strack, B.; Göttlinger, H.G. Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. *J. Virol.* **2000**, *74*, 5395–5402. [CrossRef] [PubMed]

67. Zhang, Y.; Qian, H.; Love, Z.; Barklis, E. Analysis of the assembly function of the human immunodeficiency virus type 1 Gag protein nucleocapsid domain. *J. Virol.* **1998**, *72*, 1782–1789. [PubMed]

68. Smyth, R.P.; Despons, L.; Huili, G.; Bernacchi, S.; Hijnen, M.; Mak, J.; Jossinet, F.; Weixi, L.; Paillart, J.; von Kleist, M.; et al. Mutational interference mapping experiment (MIME) for studying RNA structure and function. *Nat. Methods* **2015**, *12*, 866–872. [CrossRef] [PubMed]

69. Chen, J.; Nikolaitchik, O.A.; Singh, J.; Wright, A.; Bencsics, C.E.; Coffin, J.M.; Ni, N.; Lockett, S.; Pathak, V.K.; Hu, W.-S. High efficiency of HIV-1 genomic RNA packaging and heterozygote formation revealed by single virion analysis. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 13535–13540. [CrossRef] [PubMed]

70. Paillart, J.C.; Marquet, R.; Skripkin, E.; Ehresmann, B.; Ehresmann, C. Mutational analysis of the bipartite dimer linkage structure of human immunodeficiency virus type 1 genomic RNA. *J. Biol. Chem.* **1994**, *269*, 27486–27493. [PubMed]

71. Paillart, J.C.; Skripkin, E.; Ehresmann, B.; Ehresmann, C.; Marquet, R. A loop-loop "kissing" complex is the essential part of the dimer linkage of genomic HIV-1 RNA. *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 5572–5577. [CrossRef] [PubMed]

72. Skripkin, E.; Paillart, J.C.; Marquet, R.; Ehresmann, B.; Ehresmann, C. Identification of the primary site of the human immunodeficiency virus type 1 RNA dimerization in vitro. *Proc. Natl. Acad. Sci. USA* **1994**, *91*, 4945–4949. [CrossRef] [PubMed]
73. Skripkin, E.; Paillart, J.C.; Marquet, R.; Blumenfeld, M.; Ehresmann, B.; Ehresmann, C. Mechanisms of inhibition of in vitro dimerization of HIV type I RNA by sense and antisense oligonucleotides. *J. Biol. Chem.* **1996**, *271*, 28812–28817. [PubMed]

74. Jones, K.L.; Sonza, S.; Mak, J. Primary T-lymphocytes rescue the replication of HIV-1 DIS RNA mutants in part by facilitating reverse transcription. *Nucleic Acids Res.* **2008**, *36*, 1578–1588. [CrossRef] [PubMed]

75. Paillart, J.C.; Berthoux, L.; Ottmann, M.; Darlix, J.L.; Marquet, R.; Ehresmann, B.; Ehresmann, C. A dual role of the putative RNA dimerization initiation site of human immunodeficiency virus type 1 in genomic RNA packaging and proviral DNA synthesis. *J. Virol.* **1996**, *70*, 8348–8354. [PubMed]

76. Houzet, L.; Paillart, J.C.; Smagulova, F.; Maurel, S.; Morichaud, Z.; Marquet, R.; Mougel, M. HIV controls the selective packaging of genomic, spliced viral and cellular RNAs into virions through different mechanisms. *Nucleic Acids Res.* **2007**, *35*, 2695–2704. [CrossRef] [PubMed]

77. Balakrishnan, M.; Fay, P.J.; Bambara, R.A. The kissing hairpin sequence promotes recombination within the HIV-1 5' leader region. *J. Biol. Chem.* **2001**, *276*, 36482–36492. [CrossRef] [PubMed]

78. Smyth, R.P.; Davenport, M.P.; Mak, J. The origin of genetic diversity in HIV-1. *Virus Res.* **2012**, *169*, 415–429. [CrossRef] [PubMed]

79. Smyth, R.P.; Schlub, T.E.; Grimm, A.J.; Waugh, C.; Ellenberg, P.; Chopra, A.; Mallal, S.; Cromer, D.; Mak, J.; Davenport, M.P. Identifying Recombination Hot Spots in the HIV-1 Genome. *J. Virol.* **2014**, *88*, 2891–2902. [CrossRef] [PubMed]

80. Song, R.; Kafaie, J.; Yang, L.; Laughrea, M. HIV-1 viral RNA is selected in the form of monomers that dimerize in a three-step protease-dependent process; the DIS of stem-loop 1 initiates viral RNA dimerization. *J. Mol. Biol.* **2007**, *371*, 1084–1098. [CrossRef] [PubMed]

81. Hill, M.K.; Shehu-Xhilaga, M.; Campbell, S.M.; Poumbourios, P.; Crowe, S.M.; Mak, J. The dimer initiation sequence stem-loop of human immunodeficiency virus type 1 is dispensable for viral replication in peripheral blood mononuclear cells. *J. Virol.* **2003**, *77*, 8329–8335. [CrossRef] [PubMed]

82. Moore, M.D.; Fu, W.; Nikolaitchik, O.A.; Chen, J.; Ptak, R.G.; Hu, W.-S. Dimer initiation signal of human immunodeficiency virus type 1: Its role in partner selection during RNA copackaging and its effects on recombination. *J. Virol.* **2007**, *81*, 4002–4011. [CrossRef] [PubMed]

83. Shen, N.; Jetté, L.; Liang, C.; Wainberg, M.A.; Laughrea, M. Impact of human immunodeficiency virus type 1 RNA dimerization on viral infectivity and of stem-loop B on RNA dimerization and reverse transcription and dissociation of dimerization from packaging. *J. Virol.* **2000**, *74*, 5729–5735. [CrossRef] [PubMed]

84. Berkhout, B.; van Wamel, J.L. Role of the DIS hairpin in replication of human immunodeficiency virus type 1. *J. Virol.* **1996**, *70*, 6723–6732. [PubMed]

85. Sakuragi, J.I.; Panganiban, A.T. Human immunodeficiency virus type 1 RNA outside the primary encapsidation and dimer linkage region affects RNA dimer stability in vivo. *J. Virol.* **1997**, *71*, 3250–3254. [PubMed]

86. Harrison, G.P.; Lever, A.M. The human immunodeficiency virus type 1 packaging signal and major splice donor region have a conserved stable secondary structure. *J. Virol.* **1992**, *66*, 4144–4153. [PubMed]

87. Harrison, G.P.; Miele, G.; Hunter, E.; Lever, A.M. Functional analysis of the core human immunodeficiency virus type 1 packaging signal in a permissive cell line. *J. Virol.* **1998**, *72*, 5886–5896. [PubMed]

88. Paillart, J.C.; Dettenhofer, M.; Yu, X.F.; Ehresmann, C.; Ehresmann, B.; Marquet, R. First snapshots of the HIV-1 RNA structure in infected cells and in virions. *J. Biol. Chem.* **2004**, *279*, 48397–48403. [CrossRef] [PubMed]

89. Siegfried, N.A.; Busan, S.; Rice, G.M.; Nelson, J.A.E.; Weeks, K.M. RNA motif discovery by SHAPE and mutational profiling (SHAPE-MaP). *Nat. Methods* **2014**, *11*, 959–965. [CrossRef] [PubMed]

90. Watts, J.M.; Dang, K.K.; Gorelick, R.J.; Leonard, C.W.; Bess, J.W., Jr.; Swanstrom, R.; Burch, C.L.; Weeks, K.M. Architecture and secondary structure of an entire HIV-1 RNA genome. *Nature* **2009**, *460*, 711–716. [CrossRef] [PubMed]

91. Clavel, F.; Orenstein, J.M. A mutant of human immunodeficiency virus with reduced RNA packaging and abnormal particle morphology. *J. Virol.* **1990**, *64*, 5230–5234. [PubMed]

92. D'Souza, V.; Summers, M.F. How retroviruses select their genomes. *Nat. Rev. Microbiol.* **2005**, *3*, 643–655. [CrossRef] [PubMed]

93. Berkowitz, R.; Fisher, J.; Goff, S.P. RNA packaging. *Curr. Top. Microbiol. Immunol.* **1996**, *214*, 177–218. [PubMed]
94. Helga-Maria, C.; Hammarskjöld, M.L.; Rekosh, D. An intact TAR element and cytoplasmic localization are necessary for efficient packaging of human immunodeficiency virus type 1 genomic RNA. *J. Virol.* **1999**, *73*, 4127–4135. [PubMed]

95. Russell, R.S.; Hu, J.; Laughrea, M.; Wainberg, M.A.; Liang, C. Deficient dimerization of human immunodeficiency virus type 1 RNA caused by mutations of the u5 RNA sequences. *Virology* **2002**, *303*, 152–163. [CrossRef] [PubMed]

96. Clever, J.L.; Miranda, D.; Parslow, T.G.; Miranda, D., Jr.; Parslow, T.G. RNA structure and packaging signals in the 5' leader region of the human immunodeficiency virus type 1 genome. *J. Virol.* **2002**, *76*, 12381–12387. [CrossRef] [PubMed]

97. Laughrea, M.; Jetté, L.; Mak, J.; Kleiman, L.; Liang, C.; Wainberg, M.A. Mutations in the kissing-loop hairpin of human immunodeficiency virus type 1 reduce viral infectivity as well as genomic RNA packaging and dimerization. *J. Virol.* **1997**, *71*, 3397–3406. [PubMed]

98. Göttlinger, H.G.; Dorfman, T.; Sodroski, J.G.; Haseltine, W.A. Effect of mutations affecting the p6 Gag protein on human immunodeficiency virus particle release. *Proc. Natl. Acad. Sci. USA* **1991**, *88*, 3195–3199. [CrossRef] [PubMed]

99. Huang, M.; Orenstein, J.M.; Martin, M.A.; Freed, E.O. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. *J. Virol.* **1995**, *69*, 6810–6818. [PubMed]

100. Demirov, D.G.; Orenstein, J.M.; Freed, E.O. The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner. *J. Virol.* **2002**, *76*, 105–117. [CrossRef] [PubMed]

101. McKinstry, W.J.; Hijnen, M.; Tanwar, H.S.; Sparrow, L.G.; Nagarajan, S.; Pham, S.T.; Mak, J. Expression and purification of soluble recombinant full length HIV-1 Pr55(Gag) protein in *Escherichia coli*. *Protein Expr. Purif.* **2014**, *100*, 10–18. [CrossRef] [PubMed]

102. Wilkinson, K.A.; Gorelick, R.J.; Vasa, S.M.; Guex, N.; Rein, A.; Mathews, D.H.; Giddings, M.C.; Weeks, K.M. High-throughput SHAPE analysis reveals structures in HIV-1 genomic RNA strongly conserved across distinct biological states. *PLoS Biol.* **2008**, *6*, e96. [CrossRef] [PubMed]

103. Kenyon, J.C.; Prestwood, L.J.; Lever, A.M.L. A novel combined RNA-protein interaction analysis distinguishes HIV-1 Gag protein binding sites from structural change in the viral RNA leader. *Sci. Rep.* **2015**, *5*, 14369. [CrossRef] [PubMed]

104. Harrich, D.; Hooker, C.W.; Parry, E. The human immunodeficiency virus type 1 TAR RNA upper stem-loop plays distinct roles in reverse transcription and RNA packaging. *J. Virol.* **2000**, *74*, 5639–5646. [CrossRef] [PubMed]

105. McBride, M.S.; Schwartz, M.D.; Panganiban, A.T. Efficient encapsidation of human immunodeficiency virus type 1 vectors and further characterization of *cis* elements required for encapsidation. *J. Virol.* **1997**, *71*, 4544–4554. [PubMed]

106. Didierlaurent, L.; Racine, P.J.; Houzet, L.; Chamontin, C.; Berkhout, B.; Mougel, M. Role of HIV-1 RNA and protein determinants for the selective packaging of spliced and unspliced viral RNA and host U6 and 7SL RNA in virus particles. *Nucleic Acids Res.* **2011**, *39*, 8915–8927. [CrossRef] [PubMed]

107. Nikolaitchik, O.A.; Hu, W.-S. Deciphering the role of the Gag-Pol ribosomal frameshift signal in HIV-1 RNA genome packaging. *J. Virol.* **2014**, *88*, 4040–4046. [CrossRef] [PubMed]

108. Nikolaitchik, O.A.; Moore, M.D.; Chen, J.; Hammarskjöld, M.-L.; Rekosh, D.; Hu, W.-S. Probing the HIV-1 genomic RNA trafficking pathway and dimerization by genetic recombination and single virion analyses. *PLoS Pathog.* **2009**, *5*, e1000627.

109. Sakuragi, J.; Shioda, T.; Panganiban, A.T. Duplication of the primary encapsidation and dimer linkage region of human immunodeficiency virus type 1 RNA results in the appearance of monomeric RNA in virions. *J. Virol.* **2001**, *75*, 2557–2565. [CrossRef] [PubMed]

110. Chen, J.; Rahman, S.A.; Nikolaitchik, O.A.; Grunwald, D.; Sardo, L.; Burdick, R.C.; Plisov, S.; Liang, E.; Tai, S.; Pathak, V.K.; et al. HIV-1 RNA genome dimerizes on the plasma membrane in the presence of Gag protein. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, E201–E208. [CrossRef] [PubMed]

111. Clever, J.L.; Parslow, T.G. Mutant human immunodeficiency virus type 1 genomes with defects in RNA dimerization or encapsidation. *J. Virol.* **1997**, *71*, 3407–3414. [PubMed]
112. Ooms, M.; Verhoef, K.; Southern, E.; Huthoff, H.; Berkhout, B. Probing alternative foldings of the HIV-1 leader RNA by antisense oligonucleotide scanning arrays. *Nucleic Acids Res.* **2004**, *32*, 819–827. [CrossRef] [PubMed]

113. Paillart, J.C.; Marquet, R.; Skripkin, E.; Ehresmann, C.; Ehresmann, B. Dimerization of retroviral genomic RNAs: Structural and functional implications. *Biochimie* **1996**, *78*, 639–653. [CrossRef]

114. Russell, R.S.; Liang, C.; Wainberg, M.A. Is HIV-1 RNA dimerization a prerequisite for packaging? Yes, no, probably? *Retrovirology* **2004**, *1*, 23. [CrossRef] [PubMed]

115. Aktar, S.J.; Jabeen, A.; Ali, L.M.; Vivet-Boudou, V.; Marquet, R.; Rizvi, T.A. SHAPE analysis of the 5' end of the Mason-Pfizer monkey virus (MPMV) genomic RNA reveals structural elements required for genome dimerization. *RNA* **2013**, *19*, 1648–1658. [CrossRef] [PubMed]

116. Aktar, S.J.; Vivet-Boudou, V.; Ali, L.M.; Jabeen, A.; Kalloush, R.M.; Richer, D.; Mustafa, F.; Marquet, R.; Rizvi, T.A. Structural basis of genomic RNA (gRNA) dimerization and packaging determinants of mouse mammary tumor virus (MMTV). *Retrovirology* **2014**, *11*, 96. [CrossRef] [PubMed]

117. Kalloush, R.M.; Vivet-Boudou, V.; Ali, L.M.; Mustafa, F.; Marquet, R.; Rizvi, T.A. Packaging of Mason-Pfizer monkey virus (MPMV) genomic RNA depends upon conserved long-range interactions (LRIs) between U5 and Gag sequences. *RNA* **2016**, *22*, 905–919. [CrossRef] [PubMed]

118. Huthoff, H.; Berkhout, B. Two alternating structures of the HIV-1 leader RNA. *RNA* **2001**, *7*, 143–157. [CrossRef] [PubMed]

119. Miele, G.; Mouland, A.; Harrison, G.P.; Cohen, E.; Lever, A.M. The human immunodeficiency virus type 1 5' packaging signal structure affects translation but does not function as an internal ribosome entry site structure. *J. Virol.* **1996**, *70*, 944–951. [PubMed]

120. Damgaard, C.K.; Andersen, E.S.; Knudsen, B.; Gorodkin, J.; Kjems, J. RNA interactions in the 5' region of the HIV-1 genome. *J. Mol. Biol.* **2004**, *336*, 369–379. [CrossRef] [PubMed]

121. Tran, T.; Liu, Y.; Marchant, J.; Monti, S.; Seu, M.; Zaki, J.; Yang, A.L.; Bohn, J.; Ramakrishnan, V.; Singh, R.; et al. Conserved determinants of lentiviral genome dimerization. *Retrovirology* **2015**, *12*, 83. [CrossRef] [PubMed]

122. Heng, X.; Kharytonchyk, S.; Garcia, E.L.; Lu, K.; Divakaruni, S.S.; Lacotti, C.; Edme, K.; Telesnitsky, A.; Summers, M.F. Identification of a Minimal Region of the HIV-1 5'-Leader Required for RNA Dimerization, NC Binding, and Packaging. *J. Mol. Biol.* **2012**, *417*, 224–239. [CrossRef] [PubMed]

123. Song, R.; Kafaie, J.; Laughrea, M. Role of the 5' TAR stem-loop and the U5-AUG duplex in dimerization of HIV-1 genomic RNA. *Biochemistry* **2008**, *47*, 3283–3293. [CrossRef] [PubMed]

124. Eckwahl, M.J.; Arnion, H.; Kharytonchyk, S.; Zang, T.; Bieniasz, P.D.; Telesnitsky, A.; Wolin, S.L. Analysis of the human immunodeficiency virus-1 RNA packageome. *RNA* **2016**, *22*, 1228–1238. [CrossRef] [PubMed]

125. Muriaux, D.; Rein, A. Encapsulation and transduction of cellular genes by retroviruses. *Front. Biosci.* **2003**, *8*, d135–d142. [PubMed]

126. Onafuwa-Nuga, A.A.; Telesnitsky, A.; King, S.R. 7SL RNA, but not the 54-kd signal recognition particle protein, is an abundant component of both infectious HIV-1 and minimal virus-like particles. *RNA* **2006**, *12*, 542–546. [CrossRef] [PubMed]

127. Rulli, S.J.; Hibbert, C.S.; Mirro, J.; Pederson, T.; Biswal, S.; Rein, A. Selective and nonselective packaging of cellular RNAs in retrovirus particles. *J. Virol.* **2007**, *81*, 6623–6631. [CrossRef] [PubMed]

128. Eckwahl, M.J.; Telesnitsky, A.; Wolin, S.L. Host RNA packaging by retroviruses: A newly synthesized story. *mBio* **2016**, *7*, e02025-15. [CrossRef] [PubMed]

129. Telesnitsky, A.; Wolin, S.L. The host RNAs in retroviral particles. *Viruses* **2016**, *8*, 235. [CrossRef] [PubMed]

130. Campbell, S.; Vogt, V.M. Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1. *J. Virol.* **1995**, *69*, 6487–6497. [PubMed]

131. Hendrix, J.; Baumgärtel, V.; Schrimpf, W.; Ivanchenko, S.; Digman, M.A.; Gratton, E.; Kräusslich, H.-G.; Müller, B.; Lamb, D.C. Live-cell observation of cytosolic HIV-1 assembly onset reveals RNA-interacting Gag oligomers. *J. Cell Biol.* **2015**, *210*, 629–646. [CrossRef] [PubMed]

132. Jouvenet, N.; Lainé, S.; Pessel-Vivares, L.; Mougel, M. Cell biology of retroviral RNA packaging. *RNA Biol.* **2011**, *8*, 572–580. [CrossRef] [PubMed]

133. Garbitt-Hirst, R.; Kenney, S.P.; Parent, L.J. Genetic evidence for a connection between Rous sarcoma virus Gag nuclear trafficking and genomic RNA packaging. *J. Virol.* **2009**, *83*, 6790–6797. [CrossRef] [PubMed]
134. Scheifele, L.Z.; Garbitt, R.A.; Rhoads, J.D.; Parent, L.J. Nuclear entry and CRM1-dependent nuclear export of the Rous sarcoma virus Gag polyprotein. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 3944–3949. [CrossRef] [PubMed]

135. Gudleski, N.; Flanagan, J.M.; Ryan, E.P.; Bewley, M.C.; Parent, L.J. Directionality of nucleocytoplasmic transport of the retroviral Gag protein depends on sequential binding of karyopherins and viral RNA. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 9358–9363. [CrossRef] [PubMed]

136. Stake, M.S.; Bann, D.V.; Kaddis, R.J.; Parent, L.J. Nuclear trafficking of retroviral RNAs and Gag proteins during late steps of replication. *Viruses* **2013**, *5*, 2767–2795. [CrossRef] [PubMed]

137. Baluyot, M.F.; Grosse, S.A.; Lyddon, T.D.; Janaka, S.K.; Johnson, M.C. CRM1-dependent trafficking of retroviral Gag proteins revisited. *J. Virol.* **2012**, *86*, 4696–4700. [CrossRef] [PubMed]

138. Lochmann, T.L.; Bann, D.V.; Ryan, E.P.; Beyer, A.R.; Mao, A.; Cochrane, A.; Parent, L.J. NC-mediated nucleolar localization of retroviral Gag proteins. *Virus Res.* **2013**, *171*, 304–318. [CrossRef] [PubMed]

139. Yu, K.L.; Lee, S.H.; Lee, E.S.; You, J.C. HIV-1 nucleocapsid protein localizes efficiently to the nucleus and nucleolus. *Virology* **2016**, *492*, 204–212. [CrossRef] [PubMed]

140. Grewe, B.; Hoffmann, B.; Ohs, I.; Blissenbach, M.; Brandt, S.; Tippler, B.; Grunwald, T.; Überla, K. Cytoplasmic utilization of human immunodeficiency virus type 1 genomic RNA is not dependent on a nuclear interaction with Gag. *J. Virol.* **2012**, *86*, 2990–3002. [CrossRef] [PubMed]

141. Ferrer, M.; Clerté, C.; Chamontin, C.; Basyuk, E.; Lainé, S.; Hottin, J.; Bertrand, E.; Margeat, E.; Mougel, M. Imaging HIV-1 RNA dimerization in cells by multicolor super-resolution and fluctuation microscopies. *Nucleic Acids Res.* **2016**. [CrossRef] [PubMed]

142. Jouvenet, N.; Bieniasz, P.D.; Simon, S.M. Imaging the biogenesis of individual HIV-1 virions in live cells. *Nature* **2008**, *454*, 236–240. [CrossRef] [PubMed]

143. Kemler, I.; Meehan, A.; Poeschla, E.M. Live-cell coimaging of the genomic RNAs and Gag proteins of two lentiviruses. *J. Virol.* **2010**, *84*, 6352–6366. [CrossRef] [PubMed]

144. Kutluay, S.B.; Bieniasz, P.D. Analysis of the initiating events in HIV-1 particle assembly and genome packaging. *PLoS Pathog.* **2010**, *6*, e1001200. [CrossRef] [PubMed]

145. Poole, E.; Strappe, P.; Mok, H.-P.; Hicks, R.; Lever, A.M.L. HIV-1 Gag-RNA interaction occurs at a perinuclear/centrosomal site; analysis by confocal microscopy and FRET. *Traffic* **2005**, *6*, 741–755. [CrossRef] [PubMed]

146. Bernacchi, S. HIV-1 Pr55Gag binds genomic and spliced RNAs with different affinity and stoichiometry. **2016**, unpublished.

147. Ott, D.E.; Coren, L.V.; Kane, B.P.; Busch, L.K.; Johnson, D.G.; Sowder, R.C.; Chertova, E.N.; Arthur, L.O.; Henderson, L.E. Cytoskeletal proteins inside human immunodeficiency virus type 1 virions. *J. Virol.* **1996**, *70*, 7734–7743. [PubMed]

148. Gladnikoff, M.; Shimoni, E.; Gov, N.S.; Rousso, I. Retroviral assembly and budding occur through an actin-driven mechanism. *Biophys. J.* **2009**, *97*, 2419–2428. [CrossRef] [PubMed]

149. Jouvenet, N.; Neil, S.J.D.; Bess, C.; Johnson, M.C.; Virgen, C.A.; Simon, S.M.; Bieniasz, P.D. Plasma membrane is the site of productive HIV-1 particle assembly. *PLoS Biol.* **2006**, *4*, e435. [CrossRef] [PubMed]

150. Rahman, S.A.; Koch, P.; Weichsel, J.; Godinez, W.J.; Schwarz, U.; Rohr, K.; Lamb, D.C.; Kräusslich, H.-G.; Müller, B. Investigating the role of F-actin in human immunodeficiency virus assembly by live-cell microscopy. *J. Virol.* **2014**, *88*, 7904–7914. [CrossRef] [PubMed]

151. Lingappa, J.R.; Dooher, J.E.; Newman, M.A.; Kiser, P.K.; Klein, K.C. Basic residues in the nucleocapsid domain of Gag are required for interaction of HIV-1 Gag with ABCE1 (HP68), a cellular protein important for HIV-1 capsid assembly. *J. Biol. Chem.* **2006**, *281*, 3773–3784. [CrossRef] [PubMed]

152. Robinson, B.A.; Reed, J.C.; Geary, C.D.; Swain, J.V.; Lingappa, J.R. A temporospatial map that defines specific steps at which critical surfaces in the Gag MA and CA domains act during immature HIV-1 capsid assembly in cells. *J. Virol.* **2014**, *88*, 5718–5741. [CrossRef] [PubMed]

153. Mouland, A.J.; Mercier, J.; Luo, M.; Bernier, L.; DesGroseillers, L.; Cohen, E.A. The double-stranded RNA-binding protein Staufen is incorporated in human immunodeficiency virus type 1: Evidence for a role in genomic RNA encapsidation. *J. Virol.* **2000**, *74*, 5441–5451. [CrossRef] [PubMed]

154. Reed, J.C.; Molter, B.; Geary, C.D.; McNevin, J.; McElrath, J.; Giri, S.; Klein, K.C.; Lingappa, J.R. HIV-1 Gag co-opts a cellular complex containing DDX6, a helicase that facilitates capsid assembly. *J. Cell Biol.* **2012**, *198*, 439–456. [CrossRef] [PubMed]
155. Chatel-Chaix, L.; Clément, J.-F.; Martel, C.; Bériault, V.; Gatignol, A.; DesGroseillers, L.; Mouland, A.J. Identification of Staufen in the human immunodeficiency virus type 1 Gag ribonucleoprotein complex and a role in generating infectious viral particles. *Mol. Cell. Biol.* **2004**, *24*, 2637–2648. [CrossRef] [PubMed]

156. Balasubramaniam, M.; Freed, E.O. New insights into HIV assembly and trafficking. *Physiology* **2011**, *26*, 236–251. [CrossRef] [PubMed]

157. Grigorov, B.; Arcanger, F.; Roingeard, P.; Darlix, J.-L.; Muriaux, D. Assembly of infectious HIV-1 in human epithelial and T-lymphoblastic cell lines. *J. Mol. Biol.* **2006**, *359*, 848–862. [CrossRef] [PubMed]

158. Perlman, M.; Resh, M.D. Identification of an intracellular trafficking and assembly pathway for HIV-1 Gag. *Traffic* **2006**, *7*, 731–745. [CrossRef] [PubMed]

159. Dong, X.; Li, H.; Derdowski, A.; Ding, L.; Burnett, A.; Chen, X.; Peters, T.R.; Dermody, T.S.; Woodruff, E.; Wang, J.-J.; et al. AP-3 directs the intracellular trafficking of HIV-1 Gag and plays a key role in particle assembly. *Cell* **2005**, *120*, 663–674. [CrossRef] [PubMed]

160. Welsch, S.; Müller, B.; Kräusslich, H.-G. More than one door—Budding of enveloped viruses through cellular membranes. *FEBS Lett.* **2007**, *581*, 2089–2097. [CrossRef] [PubMed]

161. Jouvenet, N.; Simon, S.M.; Bieniasz, P.D. Imaging the interaction of HIV-1 genomes and Gag during assembly of individual viral particles. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 19114–19119. [CrossRef] [PubMed]

162. Sardo, L.; Hatch, S.C.; Chen, J.; Nikolaitchik, O.; Burdick, R.C.; Chen, D.; Westlake, C.J.; Lockett, S.; Pathak, V.K.; Hu, W.-S. Dynamics of HIV-1 RNA Near the Plasma Membrane during Virus Assembly. *J. Virol.* **2015**, *89*, 10832–10840. [CrossRef] [PubMed]

163. Bell, N.M.; Lever, A.M.L. HIV Gag polyprotein: Processing and early viral particle assembly. *Trends Microbiol.* **2013**, *21*, 136–144. [CrossRef] [PubMed]

164. Könnyű, B.; Sadiq, S.K.; Turányi, T.; Hírmondó, R.; Müller, B.; Kräusslich, H.-G.; Coveney, P.V.; Müller, V. Gag-Pol processing during HIV-1 virion maturation: A systems biology approach. *PLoS Comput. Biol.* **2013**, *9*, e1003103. [CrossRef] [PubMed]

165. Mattei, S.; Anders, M.; Konvalinka, J.; Kräusslich, H.-G.; Briggs, J.A.G.; Müller, B. Induced maturation of human immunodeficiency virus. *J. Virol.* **2014**, *88*, 13722–13731. [CrossRef] [PubMed]

166. Kaplan, A.H.; Zack, J.A.; Knigge, M.; Paul, D.A.; Kempf, D.J.; Norbeck, D.W.; Swanstrom, R. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. *J. Virol.* **1993**, *67*, 4050–4055. [PubMed]

167. Müller, B.; Anders, M.; Akiyama, H.; Welsch, S.; Glass, B.; Nikovics, K.; Clavel, F.; Tervo, H.-M.; Keppler, O.T.; Kräusslich, H.-G. HIV-1 Gag processing intermediates *trans*-dominantly interfere with HIV-1 infectivity. *J. Biol. Chem.* **2009**, *284*, 29692–29703. [CrossRef] [PubMed]

168. Fu, W.; Rein, A. Maturation of dimeric viral RNA of Moloney murine leukemia virus. *J. Virol.* **1993**, *67*, 5443–5449. [PubMed]

169. Grohman, J.K.; Gorelick, R.J.; Kottegoda, S.; Allbritton, N.L.; Rein, A.; Weeks, K.M. An immature retroviral RNA genome resembles a kinetically trapped intermediate state. *J. Virol.* **2014**, *88*, 6061–6068. [CrossRef] [PubMed]

170. Fu, W.; Gorelick, R.J.; Rein, A. Characterization of human immunodeficiency virus type 1 dimeric RNA from wild-type and protease-defective virions. *J. Virol.* **1994**, *68*, 5013–5018. [PubMed]

171. Fu, W.; Dang, Q.; Nagashima, K.; Freed, E.O.; Pathak, V.K.; Hu, W.-S. Effects of Gag mutation and processing on retroviral dimeric RNA maturation. *J. Virol.* **2006**, *80*, 1242–1249. [CrossRef] [PubMed]

172. Levin, J.G.; Guo, J.; Rouzina, I.; Musier-Forsyth, K. Nucleic acid chaperone activity of HIV-1 nucleocapsid protein: Critical role in reverse transcription and molecular mechanism. *Prog. Nucleic Acid Res. Mol. Biol.* **2005**, *80*, 217–286. [PubMed]

173. Ohishi, M.; Nakano, T.; Sakuragi, S.; Shioda, T.; Sano, K.; Sakuragi, J. The relationship between HIV-1 genome RNA dimerization, virion maturation and infectivity. *Nucleic Acids Res.* **2011**, *39*, 3404–3417. [CrossRef] [PubMed]

174. Rein, A.; Henderson, L.E.; Levin, J.G. Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: Significance for viral replication. *Trends Biochem. Sci.* **1998**, *23*, 297–301. [CrossRef]

175. De Marco, A.; Müller, B.; Glass, B.; Riches, J.D.; Kräusslich, H.-G.; Briggs, J.A.G. Structural analysis of HIV-1 maturation using cryo-electron tomography. *PLoS Pathog.* **2010**, *6*, e1001215. [CrossRef] [PubMed]
176. Wang, W.; Naiyer, N.; Mitra, M.; Li, J.; Williams, M.C.; Rouzina, I.; Gorelick, R.J.; Wu, Z.; Musier-Forsyth, K. Distinct nucleic acid interaction properties of HIV-1 nucleocapsid protein precursor NCp15 explain reduced viral infectivity. *Nucleic Acids Res.* **2014**, *42*, 7145–7159. [CrossRef] [PubMed]

177. Wu, T.; Gorelick, R.J.; Levin, J.G. Selection of fully processed HIV-1 nucleocapsid protein is required for optimal nucleic acid chaperone activity in reverse transcription. *Virus Res.* **2014**, *193*, 52–64. [CrossRef] [PubMed]

178. Wu, T.; Datta, S.A.K.; Mitra, M.; Gorelick, R.J.; Rein, A.; Levin, J.G. Fundamental differences between the nucleic acid chaperone activities of HIV-1 nucleocapsid protein and Gag or Gag-derived proteins: Biological implications. *Virology* **2010**, *405*, 556–567. [CrossRef] [PubMed]

179. Guo, F.; Saadatmand, J.; Niu, M.; Kleiman, L. Roles of Gag and NCp7 in facilitating tRNA(Lys)(3) Annealing to viral RNA in human immunodeficiency virus type 1. *J. Virol.* **2009**, *83*, 8099–8107. [CrossRef] [PubMed]

180. Seif, E.; Niu, M.; Kleiman, L. In virio SHAPE analysis of tRNA(Lys3) annealing to HIV-1 genomic RNA in wild type and protease-deficient virus. *Retrovirology* **2015**, *12*, 40. [CrossRef] [PubMed]

181. Lapadat-Tapolsky, M.; Pernelle, C.; Borie, C.; Darlix, J.L. Analysis of the nucleic acid annealing activities of nucleocapsid protein from HIV-1. *Nucleic Acids Res.* **1995**, *23*, 2434–2441. [CrossRef] [PubMed]

182. Vo, M.-N.; Barany, G.; Rouzina, I.; Musier-Forsyth, K. HIV-1 nucleocapsid protein switches the pathway of transactivation response element RNA/DNA annealing from loop-loop "kissing" to "zipper". *J. Mol. Biol.* **2009**, *386*, 789–801. [CrossRef] [PubMed]

183. Belfetmi, A.; Zargarian, L.; Tisné, C.; Sleiman, D.; Morellet, N.; Lescop, E.; Maskri, O.; René, B.; Mély, Y.; Fossé, P.; et al. Insights into the mechanisms of RNA secondary structure destabilization by the HIV-1 nucleocapsid protein. *RNA* **2016**, *22*, 506–517. [CrossRef] [PubMed]

184. Didierlaurent, L.; Houzet, L.; Morichaud, Z.; Darlix, J.-L.; Mougel, M. The conserved N-terminal basic residues and zinc-finger motifs of HIV-1 nucleocapsid restrict the viral cDNA synthesis during virus formation and maturation. *Nucleic Acids Res.* **2008**, *36*, 4745–4753. [CrossRef] [PubMed]

185. Houzet, L.; Morichaud, Z.; Didierlaurent, L.; Muriaux, D.; Darlix, J.-L.; Mougel, M. Nucleocapsid mutations turn HIV-1 into a DNA-containing virus. *Nucleic Acids Res.* **2008**, *36*, 2311–2319. [CrossRef] [PubMed]

186. Racine, P.-J.; Chamontin, C.; de Rocquigny, H.; Bernacchi, S.; Paillart, J.-C.; Mougel, M. Requirements for nucleocapsid-mediated regulation of reverse transcription during the late steps of HIV-1 assembly. *Sci. Rep.* **2016**, *6*, 27536. [CrossRef] [PubMed]

187. McCauley, M.J.; Rouzina, I.; Manthei, K.A.; Gorelick, R.J.; Musier-Forsyth, K.; Williams, M.C. Targeted binding of nucleocapsid protein transforms the folding landscape of HIV-1 TAR RNA. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 13555–13560. [CrossRef] [PubMed]

188. Rodríguez-Rodríguez, L.; Tsuchihashi, Z.; Fuentes, G.M.; Bambara, R.A.; Fay, P.J. Influence of human immunodeficiency virus nucleocapsid protein on synthesis and strand transfer by the reverse transcriptase in vitro. *J. Biol. Chem.* **1995**, *270*, 15005–15011. [CrossRef] [PubMed]

189. Liang, C.; Rong, L.; Cherry, E.; Kleiman, L.; Laughrea, M.; Wainberg, M.A. Deletion mutagenesis within the dimerization initiation site of human immunodeficiency virus type 1 results in delayed processing of the p2 peptide from precursor proteins. *J. Virol.* **1999**, *73*, 6147–6151. [PubMed]

190. L'Hernault, A.; Weiss, E.U.; Greatorex, J.S.; Lever, A.M. HIV-2 genome dimerization is required for the correct processing of Gag: A second-site reversion in matrix can restore both processes in dimerization-impaired mutant viruses. *J. Virol.* **2012**, *86*, 5867–5876. [CrossRef] [PubMed]

<figure><img src="image_6.png" /></figure>